Avid Bioservices Inc (CDMO)

[BioBS2012]

CP, JBAIN.... others. I just saw this statement on the clinicaltrials.gov site for the Nivolumab Phase III study in NSCLC (it is also being run against docetaxel and so directly relevant with PPHM's study.

Overall Survival is defined as the time from randomization to the date of death

Given the above definition, does the eventing timetables you had change upwards (meaning sooner)?
BMY is expected to release preliminary results most likely this quarter so keep an eye on what comes out.

EDIT: By the way, this Bristol Phase III had the same number of subjects 582, and has 115 centers.
http://www.clinicaltrials.gov/ct2/show/NCT01673867?term=%22nivolumab%22+AND+%22nsclc%22&rank=3